FDA Approval Alert: The Need-to-Know | Axicabtagene Ciloleucel for Relapsed/Refractory Large B-cell Lymphoma Following Chemoimmunotherapy

In April 2022, axicabtagene ciloleucel was approved by the FDA for the treatment of adult patients with large B-cell lymphoma whose disease was refractory to or which relapsed within 12 months after first-line chemoimmunotherapy.

Frederick Locke, MD, Speaks to Clinicians on the Use of Axi-cel in LBCL
Frederick Locke, MD, Speaks to Clinicians on the Use of Axi-cel in LBCL
Video
Apr 28, 2022 8:00 PM
Frederick Lock, MD, spoke about clinicians can best utilize the treatment of axicabtagene ciloleucel for patients with large B-cell lymphoma.
Frederick Locke, MD, Reviews the Next Steps for Axi-Cel in LBCL
Frederick Locke, MD, Reviews the Next Steps for Axi-Cel in LBCL
Video
Apr 21, 2022 8:00 PM
Frederick Lock, MD, spoke about how future research regarding axicabtagene ciloleucel for patients with large B-cell lymphoma will progress.
Frederick Locke, MD, Talks Unmet Needs Reduced by Axi-Cel Use in LBCL
Frederick Locke, MD, Talks Unmet Needs Reduced by Axi-Cel Use in LBCL
Video
Apr 16, 2022 2:00 PM
Frederick Lock, MD, spoke about how axicabtagene ciloleucel has improved survival in patients with large B-cell lymphoma.
Frederick Locke, MD, Discusses Recent Approval of Axi-Cel in Relapsed/Refractory LBCL
Frederick Locke, MD, Discusses Recent Approval of Axi-Cel in Relapsed/Refractory LBCL
Video
Apr 8, 2022 9:00 PM
Frederick Lock, MD, spoke about the approval of axicabtagene ciloleucel and how it’s beneficial for patients with large B-cell lymphoma who were treated with frontline chemoimmunotherapy.
FDA Grants Approval to Axi-Cel for Adults With LBCL Following First-Line Chemoimmunotherapy
FDA Grants Approval to Axi-Cel for Adults With LBCL Following First-Line Chemoimmunotherapy
Article
Apr 1, 2022 10:38 PM
Based on results of the ZUMA-7 trial, the FDA approved axicabtagene ciloleucel for the treatment of certain patients with large B-cell lymphoma who received chemoimmunotherapy in the frontline setting.